GSK的HSV疫苗候选人在中阶段试验失败,不会推进到后阶段试验。 GSK's HSV vaccine candidate fails mid-stage trial, will not advance to late-stage trials.

GlaxoSmithKline(GSK)宣布,其实验性除草虫简单病毒(HSV)疫苗候选疫苗在中阶段试验中没有达到主要目标,也不会推进后阶段试验。 GlaxoSmithKline (GSK) announced that its experimental herpes simplex virus (HSV) vaccine candidate did not achieve the primary goal in a mid-stage trial and will not advance to late-stage trials. 尽管该研究将继续进行安全监测和后续数据,但GSK强调在解决生殖器疹方面持续需要创新,全球约有6.83亿人受到影响. Although the study will continue for safety monitoring and follow-up data, GSK emphasized the ongoing need for innovation in addressing genital herpes, which affects approximately 683 million individuals globally.